Most studies have shown that the survival advantage of HER2-low tumors over HER2-zero tumors receiving chemotherapy alone was only manifested in HR-positive breast cancer,[25,30,31] while not observed in TNBC. This evidence concerns the gene ERBB2 and breast cancer.